Lazard Asset Management
FATE icon

Lazard Asset Management’s Fate Therapeutics FATE Stock Holding History

Lazard Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-89,403
Closed -$901K – 2377
2022
Q4 		$901K Sell
89,403
-71,970
-45% -$1.35M ﹤0.01% 1018
2022
Q3 		$3.62M Sell
161,373
-59,987
-27% -$1.73M 0.01% 774
2022
Q2 		$5.49M Buy
221,360
+76,571
+53% +$2.11M 0.01% 723
2022
Q1 		$5.61M Buy
144,789
+36,797
+34% +$1.42M 0.01% 736
2021
Q4 		$6.32M Buy
107,992
+62,310
+136% +$3.53M 0.01% 733
2021
Q3 		$2.71M Sell
45,682
-27,105
-37% -$2.13M ﹤0.01% 875
2021
Q2 		$6.32M Buy
72,787
+70,507
+3,092% +$5.68M 0.01% 686
2021
Q1 		$187K Buy
2,280
+697
+44% +$66.8K ﹤0.01% 1110
2020
Q4 		$143K Buy
+1,583
New +$98.3K ﹤0.01% 1136
2020
Q3 		– Sell
-117
Closed -$4K – 1645
2020
Q2 		$4K Buy
+117
New +$3.49K ﹤0.01% 1532

Other funds holding FATE

State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Lazard Asset Management's FATE Position: Q1 2023 in Review

Lazard Asset Management sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 89,403 shares — an estimated $901K sold.

Lazard Asset Management first reported a position in FATE in Q2 2020 and held it in 10 quarters. The position peaked at $6.32M in Q4 2021. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

  • Lazard Asset Management reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Lazard Asset Management sold 89,403 Fate Therapeutics shares in Q1 2023, an estimated $901K.
  • Lazard Asset Management first reported a position in Fate Therapeutics in Q2 2020 and held it in 10 quarters.
  • Lazard Asset Management's Fate Therapeutics position peaked at $6.32M in Q4 2021.
  • 181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on Lazard Asset Management's 13F filing for Q1 2023, filed 15 May 2023.